DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
+21.45%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$5.75B
AUM Growth
+$5.75B
(+6.1%)
Cap. Flow
+$243M
Cap. Flow
% of AUM
4.22%
Top 10 Holdings %
Top 10 Hldgs %
51.71%
Holding
447
New
223
Increased
64
Reduced
46
Closed
77
Top Buys
| 1 |
BioNTech
BNTX
|
$52.5M |
| 2 |
Kyverna Therapeutics
KYTX
|
$36.3M |
| 3 |
Perspective Therapeutics
CATX
|
$33.5M |
| 4 |
Larimar Therapeutics
LRMR
|
$32.6M |
| 5 |
Surgery Partners
SGRY
|
$32.3M |
Top Sells
| 1 |
CMAX
CareMax, Inc. Class A Common Stock
CMAX
|
$74M |
| 2 |
Viking Therapeutics
VKTX
|
$66.9M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$64M |
| 4 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$62.6M |
| 5 |
Baxter International
BAX
|
$57.8M |
Sector Composition
| 1 | Healthcare | 88.87% |
| 2 | Industrials | 0.71% |
| 3 | Technology | 0.31% |
| 4 | Consumer Discretionary | 0.26% |
| 5 | Financials | 0.24% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Nuvalent
NUVL
$5.52B
| $1.5B | 26.12% | 19,991,024 | – | – |
|
2
Viatris
VTRS
$12.3B
| $255M | 4.44% | 21,395,052 +1,531,568 | +8% | +$18.3M |
|
3
Centene
CNC
$14.3B
| $187M | 3.25% | 2,381,044 +389,245 | +20% | +$30.5M |
|
|
4
Larimar Therapeutics
LRMR
$310M
| $161M | 2.8% | 21,231,974 +4,290,617 | +25% | +$32.6M |
|
5
AdaptHealth
AHCO
$1.28B
| $153M | 2.65% | 13,257,940 -350,000 | -3% | -$4.03M |
|
6
Catalyst Pharmaceutical
CPRX
$2.52B
| $146M | 2.53% | 9,130,817 +241,916 | +3% | +$3.86M |
|
7
Oscar Health
OSCR
$4.31B
| $139M | 2.42% | 9,373,097 -1,873,723 | -17% | -$27.9M |
|
|
FUSN
8
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
| $136M | 2.37% | 6,401,000 | – | – |
|
9
Owens & Minor
OMI
$378M
| $135M | 2.35% | 4,877,588 -352,191 | -7% | -$9.76M |
|
10
Merus
MRUS
$4.98B
| $119M | 2.08% | 2,649,401 -370,500 | -12% | -$16.7M |
|
11
Kura Oncology
KURA
$686M
| $115M | 2.01% | 5,411,571 +98,838 | +2% | +$2.11M |
|
12
IDEAYA Biosciences
IDYA
$2.15B
| $115M | 2.01% | 2,630,292 | – | – |
|
13
ARS Pharmaceuticals
SPRY
$1.15B
| $113M | 1.97% | 11,077,927 | – | – |
|
14
Brookdale Senior Living
BKD
$1.83B
| $103M | 1.8% | 15,612,264 +819,000 | +6% | +$5.41M |
|
15
Revolution Medicines
RVMD
$7.1B
| $99.6M | 1.73% | 3,090,073 | – | – |
|
16
Neurocrine Biosciences
NBIX
$13.8B
| $95.3M | 1.66% | 691,004 -205,715 | -23% | -$28.4M |
|
|
17
Surgery Partners
SGRY
$2.91B
| $95.1M | 1.65% | 3,186,803 +1,081,294 | +51% | +$32.3M |
|
|
DCPH
18
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $80.7M | 1.4% | 5,127,270 -660,754 | -11% | -$10.4M |
|
19
HilleVax
HLVX
$105M
| $66.6M | 1.16% | 4,004,231 | – | – |
|
|
SWTX
20
DELISTED
SpringWorks Therapeutics
SWTX
| $63.2M | 1.1% | 1,283,176 -1,301,200 | -50% | -$64M |
|
21
Enhabit
EHAB
$399M
| $58.2M | 1.01% | 4,997,746 | – | – |
|
22
Nkarta
NKTX
$151M
| $56.1M | 0.98% | 5,194,087 +1,794,087 | +53% | +$19.4M |
|
23
Bio-Rad Laboratories Class A
BIO
$8.06B
| $52.7M | 0.92% | 152,378 +803 | +0.5% | +$278K |
|
|
24
BioNTech
BNTX
$24B
| $52.5M | 0.91% | +569,574 | New | +$52.5M |
|
25
Edgewise Therapeutics
EWTX
$1.51B
| $52.4M | 0.91% | 2,874,586 -1,058,551 | -27% | -$19.3M |
|